Cyclacel Pharmaceuticals Inc Share Price Nasdaq
Equities
US23254L1089
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
26/06 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
26/06 | Sector Update: Health Care Stocks Lower in Afternoon Trading | MT |
Sales 2024 * | 59.5T 49.7L | Sales 2025 * | 50T 41.77L | Capitalization | 25.46L 21Cr |
---|---|---|---|---|---|
Net income 2024 * | -1.2Cr -100.24Cr | Net income 2025 * | -1.4Cr -116.94Cr | EV / Sales 2024 * | 42.8 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 50.9 x |
P/E ratio 2024 * |
-0.35
x | P/E ratio 2025 * |
-0.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.37% |
Latest transcript on Cyclacel Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 01/97/01 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01/02/01 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 17/20/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 83 | 01/06/01 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 17/20/17 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 01/97/01 |
1st Jan change | Capi. | |
---|---|---|
+20.63% | 13TCr | |
+23.21% | 12TCr | |
+25.65% | 2.77TCr | |
-20.17% | 2.03TCr | |
-16.40% | 1.68TCr | |
-18.07% | 1.56TCr | |
+11.92% | 1.48TCr | |
-47.70% | 1.46TCr | |
+58.32% | 1.44TCr |